Clinical Trial Update: Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)

View source ↗

Summary

A recruiting clinical trial (VAPOR2) led by Imperial College London studying volatile organic compound assessment in pancreatic cancer/PDAC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Imperial College London | Conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Status: RECRUITING